^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD137 agonist

    Related drugs:
    1d
    RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Cabaletta Bio | N=12 --> 28 | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    3d
    SGNBB228-001: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    PF-08046049
    10d
    A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting --> Recruiting | Trial completion date: Mar 2028 --> Dec 2028
    Enrollment open • Trial completion date • Platinum resistant
    |
    paclitaxel
    11d
    Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment. (PubMed, Theranostics)
    Urelumab and utomilumab, are two agonistic anti-CD137 antibodies that are most advanced in clinical trials but suffer from liver toxicity and low potency, respectively. In contrast to ure-MSNs, rhCD137-MSN treatment did not induce liver damage, thereby demonstrating a more favorable safety profile than ure-MSNs. This study identifies a formulation of rhCD137L on MSNs that combines high potency with excellent safety.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    utomilumab (PF-05082566) • urelumab (BMS-663513)
    14d
    A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] (clinicaltrials.gov)
    P2, N=172, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • Imfinzi (durvalumab) • gemcitabine
    18d
    A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (clinicaltrials.gov)
    P1, N=122, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Gazyva (obinutuzumab) • clesitamig (RG6524)
    18d
    ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers. (PubMed, bioRxiv)
    Previously, we developed small molecule ULK1 inhibitors that not only inhibit ULK kinase activity but also induced the degradation of other core members of the ULK complex including ATG101 and ATG13...Finally, immunohistochemical staining of orthotopic pancreatic tumors reveals a significant increase in CD4⁺ and CD8⁺ T cell infiltration upon treatment, suggesting that SBP-1750 enhances anti-tumor immunity. These findings support further development of SBP-1750 as a novel ATG-targeting cancer therapy.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    KRAS mutation • KRAS G13
    |
    xirestomig (ATG-101)
    23d
    A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Kahr Bio Australia Pty Ltd
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    Tecentriq (atezolizumab) • Fruzaqla (fruquintinib) • DSP-107
    1m
    A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=160, Recruiting, Boehringer Ingelheim | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2027 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ezabenlimab (BI 754091) • BI 765179
    1m
    A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (clinicaltrials.gov)
    P1, N=25, Terminated, Kahr Medical | N=36 --> 25 | Trial completion date: Jun 2025 --> Oct 2025 | Active, not recruiting --> Terminated; Slow enrolment
    Enrollment change • Trial completion date • Trial termination
    |
    Venclexta (venetoclax) • azacitidine • DSP-107
    1m
    Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • acasunlimab (GEN1046)
    1m
    CAB-201-005: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Cabaletta Bio | Initiation date: Aug 2025 --> Jun 2026
    Trial initiation date
    |
    cyclophosphamide • fludarabine IV